Cereno Scientific (CRNO B) Stock Overview
A clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
CRNO B Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cereno Scientific AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 8.90 |
| 52 Week High | SEK 11.90 |
| 52 Week Low | SEK 4.70 |
| Beta | -0.057 |
| 1 Month Change | -11.79% |
| 3 Month Change | 41.27% |
| 1 Year Change | 28.61% |
| 3 Year Change | 155.38% |
| 5 Year Change | 230.86% |
| Change since IPO | 42.40% |
Recent News & Updates
Shareholder Returns
| CRNO B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -11.9% | -0.07% | 0.9% |
| 1Y | 28.6% | -8.5% | -1.0% |
Return vs Industry: CRNO B exceeded the Swedish Biotechs industry which returned -8.5% over the past year.
Return vs Market: CRNO B exceeded the Swedish Market which returned -1% over the past year.
Price Volatility
| CRNO B volatility | |
|---|---|
| CRNO B Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in SE Market | 13.8% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: CRNO B's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: CRNO B's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 10 | Sten Sorensen | www.cerenoscientific.com |
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and anti-thrombotic properties. Its drugs portfolio includes CS014, an epigenetic modulator that is in phase I for the treatment of cardiovascular, pulmonary diseases, and idiopathic pulmonary fibrosis; and preclinical drug candidates comprises CS585, a selective prostacyclin (IP) receptor agonist for the treatment of rare thrombotic diseases, such as anti phospholipid syndrome.
Cereno Scientific AB (publ) Fundamentals Summary
| CRNO B fundamental statistics | |
|---|---|
| Market cap | SEK 2.51b |
| Earnings (TTM) | -SEK 109.10m |
| Revenue (TTM) | SEK 75.71m |
Is CRNO B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRNO B income statement (TTM) | |
|---|---|
| Revenue | SEK 75.71m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 75.71m |
| Other Expenses | SEK 184.81m |
| Earnings | -SEK 109.10m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 27, 2025
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 100.00% |
| Net Profit Margin | -144.09% |
| Debt/Equity Ratio | 108.0% |
How did CRNO B perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/10 01:37 |
| End of Day Share Price | 2025/07/10 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cereno Scientific AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jyoti Prakash | Edison Investment Research |
| Soo Romanoff | Edison Investment Research |